Soligenix, Inc. - Common Stock (SNGX)
2.2000
0.00 (0.00%)
Soligenix Inc. is a biopharmaceutical company focused on developing innovative therapies for significant unmet medical needs
The company specializes in the research and clinical development of proprietary products aimed at treating rare diseases, as well as products intended for biodefense applications. With a strong emphasis on developing treatments for conditions such as oral mucositis and acute radiation syndrome, Soligenix takes a multi-faceted approach that includes leveraging its drug development platforms and engaging in collaborations with various stakeholders to advance its pipeline. The company’s dedication to improving patient outcomes drives its commitment to delivering safe and effective therapeutic options.
Previous Close | 2.200 |
---|---|
Open | 2.160 |
Bid | 2.100 |
Ask | 2.300 |
Day's Range | 2.100 - 2.220 |
52 Week Range | 1.830 - 14.92 |
Volume | 55,258 |
Market Cap | 5.52M |
PE Ratio (TTM) | 0.4632 |
EPS (TTM) | 4.8 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 36,084 |
News & Press Releases

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 25, 2025
DETROIT, MICHIGAN - February 25, 2025 ( NEWMEDIAWIRE ) - Christopher J. Schaber, Ph.D, president and CEO of Soligenix Inc. (NASDAQSNGX), was recently a guest on Benzinga’s All-Access.
Via TheNewswire.com · February 25, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 21, 2025
By Kyle Anthony, Benzinga
Via TheNewswire.com · February 21, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · February 21, 2025
Soligenix Announces Participation at the Spartan Capital Investor Conference
Premier Event to Showcase Growth Companies and Foster High-Level Investor Engagement
Via TheNewswire.com · October 29, 2024
By Kyle Anthony, Benzinga
Via TheNewswire.com · February 21, 2025

Soligenix Targets Psoriasis With New Therapy
Via News Direct · January 17, 2025

Soligenix's IIS study on HyBryte for cutaneous T-cell lymphoma shows 70% success and strong safety profile, with Phase 3 enrollment ongoing.
Via Benzinga · January 14, 2025

Soligenix Reports It Is On Cusp Of Treating Rare Cancer CTCL
Via News Direct · December 17, 2024

Soligenix opens enrollment for the Phase 3 FLASH2 study of HyBryte in early-stage CTCL, aiming to confirm extended treatment efficacy over 18 weeks.
Via Benzinga · December 16, 2024

Soligenix, A Pharmaceutical Firm Tackling Potentially Lucrative Unmet Medical Needs
Via News Direct · November 27, 2024

ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 / DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a key gathering for microcap and small-cap investors, offering a platform for investment and collaboration.
Via ACCESSWIRE · November 27, 2024

PRINCETON, NJ / ACCESSWIRE / November 15, 2024 / Soligenix, Inc. (Nasdaq:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it will be presenting at the upcoming Q4 Investor Summit and will be available for 1-on-1 meetings throughout the day.
Via ACCESSWIRE · November 15, 2024

Soligenix starts Phase 2 trial of SGX945 for Behçet's Disease, aiming to enroll 25 patients and report results by mid-2025. Trial includes efficacy assessments.
Via Benzinga · November 14, 2024

Via Benzinga · November 1, 2024

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via NewMediaWire · October 29, 2024

Via Benzinga · October 7, 2024

Via Benzinga · October 3, 2024

Via Benzinga · October 3, 2024

Via Benzinga · October 3, 2024

Via Benzinga · October 2, 2024

ORLANDO, FL / ACCESSWIRE / September 20, 2024 / RedChip Companies will air interviews with Nova Minerals Limited (Nasdaq:NVA) and Soligenix Inc. (Nasdaq:SNGX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 21, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESSWIRE · September 20, 2024

ORLANDO, FL / ACCESSWIRE / August 16, 2024 / RedChip Companies will air interviews with Soligenix Inc. (Nasdaq:SNGX) and American Resources Corp. (Nasdaq:AREC) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 17, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Via ACCESSWIRE · August 16, 2024

There are more than 2,100 stocks under $10 from which to choose in the market. If you want to find the best, use the Portfolio Grader.
Via InvestorPlace · July 31, 2024